Eikon Therapeutics
EIKN
77 hedge funds and large institutions have $344M invested in Eikon Therapeutics in 2026 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 12 closing their positions.
208% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 12
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
48% more funds holding
Funds holding: 52 → 77 (+25)
37% more capital invested
Capital invested by funds: $251M → $344M (+$93.1M)
1.89% more ownership
Funds ownership: 47.06% → 48.95% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.8M |
| 2 |
BlackRock
New York
|
+$9.82M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$3.81M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.21M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$3.88M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.03M |
| 3 |
Jane Street
New York
|
-$2.8M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.96M |
| 5 |
Blackstone Inc
New York
|
-$1.78M |
EIKN Hedge Fund Activity: Q2 2026 in Review
77 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in Eikon Therapeutics (EIKN) for Q2 2026, worth a combined $344M — up 37% from $251M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new EIKN positions and 12 closed out — a net gain of 25 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $11.8M. The largest seller was AllianceBernstein, cutting an estimated $3.88M.
- 77 institutional investors held Eikon Therapeutics (EIKN) as of Q2 2026, up from 52 in Q1 2026.
- Funds reported $344M of Eikon Therapeutics stock for Q2 2026, up 37% quarter-over-quarter.
- 37 funds opened new Eikon Therapeutics positions in Q2 2026 and 12 closed out, a net change of +25 holders.
- The largest Eikon Therapeutics buyer in Q2 2026 was Fidelity Investments, an estimated $11.8M added.
- The largest Eikon Therapeutics seller in Q2 2026 was AllianceBernstein, an estimated $3.88M sold.
Based on aggregated 13F filings for Q2 2026.